OH-PROCTER-&-GAMBLE
11.1.2021 16:02:36 CET | Business Wire | Press release
During a time when many things feel out of our control, people have taken stock of their health and are seeking ways to make a meaningful, positive impact – all from the comfort of home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005188/en/
This year, at the 2021 Consumer Electronics Show (CES), Oral-B will highlight its commitment to powering the smallest daily habits, such as using an electric toothbrush, to create the biggest positive impact on the health of your whole body, whole family and the whole planet, through its first ever virtual experience.
Located within P&G’s LifeLab Everyday virtual platform, the virtual experience will highlight Oral-B iO, the brand’s most innovative toothbrush, reimagined and redesigned from the inside out to remove 100% more plaque than a manual toothbrush.
- The unique dentist-inspired round brush head is designed to surround each tooth with its micro-vibrating bristles to reach below the gumline for a deep, professional clean feeling every day.
- The bimodal smart pressure sensor is the first of its kind to provide positive brushing feedback, identifying and guiding users to brush in the optimal pressure range to protect gums and enamel.
- The Linear Magnetic Drive System delivers controlled, consistent movements from the handle to brush tips, producing gentle micro-vibrations for a more enjoyable experience and efficiently transferring more energy directly to the bristle tips.
- The Smart Display with Personalized Brushing Modes offers an intuitive interface that provides coaching and motivation throughout the cleaning process and features up to seven brush modes for a highly personalized experience.
And this all comes together with Artificial Intelligence Tracking via the Oral-B iO App. It provides real-time individual tracking and coaching, thanks to artificial intelligence informed by thousands of recorded brushing sessions. Oral-B iO has a simple and intuitive user interface that guides consumers through a two-minute brushing session with 3D teeth tracking to ensure a professional clean feeling every time.
Recently, Oral-B partnered with Scientific American to further explore and understand the new research and innovations transforming our understanding of the connection between oral health and overall health.
“Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health,” explains Jeremy A. Abbate, VP & Publisher at Scientific American, “Gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”
Those warning signs can be as small as bleeding gums or tooth loss but can lead to more severe conditions such as heightened pregnancy complications, cognitive loss and more than double the risk of cardiovascular disease and diabetes.
In clinical tests, Oral-B iO provided a deeper cleaning of teeth and gums, allowing users to easily and effectively maintain oral health. Oral-B iO users experienced:
- 100 percent healthier gums in just one week, when compared to manual toothbrushes
- 6 times more plaque removal along the gumline, when compared to manual toothbrushes
- 83 percent of gingivitis patients moved from unhealthy to healthy gums in eight weeks
Lisa Ernst, Senior Vice President, Research & Development, Oral Care stated, “An Oral-B electric toothbrush is a powerful first step in being proactive against the risks associated with gum disease. We give consumers the power to take control of their families’ health at home with Oral-B iO, which helps prevent and reduce gingivitis for the best gum health.”
In addition, P&G’s LifeLab Everyday will feature P&G Oral Care’s newest sustainability commitments to advance healthy oral care habits to transform the health of people while reducing our impact on our planet. Healthy habits for the environment mean a world where everyone respects our planet and its natural resources by:
- Turning off the tap when brushing your teeth
- Recycling packaging and products
- Unplugging the toothbrush charger when not in use.
For more information on Oral-B iO, please visit oralb.com .
About Oral-B
Oral-B® is the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand includes manual and electric toothbrushes for children and adults, oral irrigators and interdental products, such as dental floss.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .
About Procter & Gamble’s LifeLab Everyday:
At P&G’s LifeLab Everyday is a new virtual platform that reveals how innovation at Procter & Gamble is reinventing consumer experiences and making progress toward a better future for our society and our planet. The exhibit combines robust, consumer-based insights with breakthrough science inspired by how people live, work, play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
